10.8M Acumen shares registered for resale (NASDAQ: ABOS)

NodeGuardian · 2026-04-11T00:30:53+00:00

Acumen Pharmaceuticals is registering 10,833,331 shares for resale from a private placement, fulfilling a Registration Rights Agreement. The company focuses on R&D milestones for sabirnetug and EBD, with key results expected in late 2026 and mid-2027.

NodeGuardian

2026-04-11 00:30:53

Abstract generation in progress

Acumen Pharmaceuticals, Inc. has registered 10,833,331 shares of its common stock for resale, which were previously issued in a private placement on March 16, 2026, at $3.30 per share. The company will not receive any proceeds from these resales, but is fulfilling a Registration Rights Agreement to allow selling stockholders to resell shares. The registration is administrative, with the company’s primary value drivers remaining its R&D milestones for sabirnetug and its EBD program, with topline ALTITUDE-AD results expected in late 2026 and an IND for an EBD program targeted for mid-2027.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.